Lewenhaupt A, Ekman P, Eneroth P, Kallner A
Department of Urology, Huddinge Hospital, Stockholm, Sweden.
Scand J Urol Nephrol Suppl. 1988;110:119-23.
Serum contents of prostatic acid phosphatase, neopterin, osteocalcin, tissue polypeptide antigen and CA-50 were measured before onset of treatment in 83 patients suffering from prostatic carcinoma. In an attempt to identify patients with poor prognosis the data were related to patient survival after 2 years. It was found that the standard cut off values, obtained from the upper limits of normal, healthy subjects, were sensitive but had low specificity. A better relation to prognosis was usually found at a higher discrimination limit. The degree of elevation appears more important than the elevation of the markers as such in indicating a poor prognosis. By systematic adjustment of the discrimination levels, higher specificity can be obtained with little loss of sensitivity.
在83例前列腺癌患者治疗开始前,测定了其血清前列腺酸性磷酸酶、新蝶呤、骨钙素、组织多肽抗原和CA - 50的含量。为了识别预后不良的患者,将这些数据与患者2年后的生存情况相关联。结果发现,从正常健康受试者上限获得的标准临界值具有敏感性,但特异性较低。通常在较高的鉴别界限时与预后有更好的相关性。在预示预后不良方面,标志物升高的程度似乎比标志物本身的升高更为重要。通过系统调整鉴别水平,可以在敏感性损失很小的情况下获得更高的特异性。